A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 281
- Population
- ALL · 50 Years
- Duration
- 2014-04-11 to 2017-11-15
- Intervention
- Ranibizumab 0.5 mg; Aflibercept 2.0 mg
- Comparator
- Aflibercept 2.0 mg
- Outcomes measured
- Mean Change in Square-root Area of Geographic Atrophy (GA) From Baseline to Month 24 — Baseline, Month 24; Mean Change in Square-root Area of Geographic Atrophy From Baseline to Month 12 — Baseline, Month 12; Percentage of Patients With Newly Developed Geographic Atrophy During the Overall 24 Months of the Study — Baseline, Mo…; Mean Number of Intravitreal Injections From Baseline to Month 12 and to Month 24 — Baseline, Month 12, Month 24; Mean Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 and to Month 24 — Baseline, Month 12, Mont…; Mean Change in Central Subfield Foveal Thickness (CSFT) From Baseline to Month 12 and to Month 24 — Baseline, Month 12,…; Percentage of Patients Showing no Intraretinal Fluid (IRF)/Subretinal Fluid (SRF) — Month 2, Month 12, Month 24; Percentage of Patients Showing Greater Than and Equal to 15 Letters Gain for BCVA From Baseline to Month 12 and to Mont…; Percentage of Patients Showing Less Than and Equal to 15 Letters Loss for BCVA From Baseline to Month 12 and to Month 2…; Mean Number of Times a Patient Needed to Return to Monthly Intravitreal Injections Over 24 Months — Month 24; Mean Change in Vascular Endothelial Growth Factor (VEGF) Plasma Concentration From Baseline to 7 Days After the Second…; Percentage of Patients With Change in Retinal Nerve Fibre Thickness From Baseline to Month 12 and Month 24 — Baseline,…; Percentage of Patients With Ocular Inflammation at Baseline and 7 Days Post-injection Following 3rd Mandated Intravitre…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.